GUBamy

What is GUBamy?#

GUBamy (GUB014295) is a novel long-acting peptide that acts as a dual amylin and calcitonin receptor agonist (DACRA), developed by Gubra, a Danish biotechnology company specializing in peptide-based therapeutics for metabolic diseases. The drug represents a mechanistically distinct approach to obesity treatment compared to the dominant GLP-1 receptor agonist class.

In March 2025, AbbVie entered the obesity market by licensing GUBamy from Gubra in a deal worth $350 million upfront plus potential milestones, signaling significant pharmaceutical industry interest in non-GLP-1 obesity mechanisms.

Mechanism of Action#

GUBamy acts through dual activation of amylin and calcitonin receptors:

Amylin Receptor Agonism#

Amylin (islet amyloid polypeptide, IAPP) is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Its physiological effects include:

• Appetite suppression: Acts on the area postrema in the brainstem to reduce food intake
• Gastric emptying delay: Slows gastric motility, contributing to satiety
• Glucagon suppression: Reduces postprandial glucagon secretion
• Postprandial glucose regulation: Complements insulin in glucose homeostasis

The only approved amylin analog, pramlintide (Symlin), has a short half-life requiring thrice-daily injection, limiting its practical utility. GUBamy's long-acting design (11-day half-life) overcomes this limitation.

Calcitonin Receptor Agonism#

Calcitonin receptors mediate additional metabolic effects:

• Energy expenditure: Calcitonin receptor signaling may increase energy expenditure
• Appetite regulation: Additional brainstem appetite suppression pathways
• Bone metabolism: Calcitonin naturally inhibits osteoclast activity (though the metabolic relevance in obesity treatment is unclear)

Complementary to GLP-1#

The amylin/calcitonin receptor pathway is mechanistically distinct from GLP-1 signaling:

• Different receptor targets (AMY1-3 and CTR vs GLP-1R)
• Different neuroanatomical sites of action (brainstem area postrema vs hypothalamus)
• Non-overlapping signaling cascades
• Preclinical evidence suggests additive or synergistic weight loss when combined with GLP-1 RAs

Clinical Development#

GUBamy is in early clinical development:

• Phase 1 SAD (Single Ascending Dose): Completed; demonstrated safety, dose proportionality, and dose-dependent weight loss
• Phase 1 MAD (Multiple Ascending Dose): Interim results showed 7.77% weight loss at 2 mg weekly by day 43
• AbbVie partnership: $350M upfront payment for worldwide development rights (March 2025)
• Next steps: Phase 2 trials expected under AbbVie's development

Important Considerations#

GUBamy is an early-stage investigational medication with only phase 1 data available. Key considerations include:

• Very limited clinical data (phase 1 only)
• Long-term safety and efficacy are completely unknown
• The phase 1 weight loss results, while impressive for the stage, need confirmation in larger, longer trials
• Combination therapy potential with GLP-1 RAs is theoretical and untested in clinical trials
• The 11-day half-life is advantageous for weekly dosing but means prolonged drug exposure if adverse events occur

Key Research Findings#

Gubra Announces Positive GUBamy Phase 1 SAD Data, published in Company press release (Gubra A/S, 2024):

• The study showed half life of 270 hours confirmed
• The study demonstrated weight loss of 3% in highest dose groups over 6 weeks

Gubra Announces Positive GUBamy Phase 1 Interim MAD Results, published in Company press release (Gubra A/S, 2024):

• The study showed LS mean weight loss of 7.77% at day 43 with GUBamy 2 mg weekly
• The study showed weight change at day 43 of 1.99%

Related Reading#

• GUBamy research studies and evidence
• GUBamy dosing protocols
• GUBamy side effects profile
• Pramlintide (Symlin) research guide
• Cagrilintide research guide